Shanghai Junshi Biosciences Co., Ltd. (SHJBF)
| Market Cap | 3.84B -23.4% |
| Revenue (ttm) | 477.94M +29.1% |
| Net Income | -63.91M |
| EPS | -0.06 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Open | 3.350 |
| Previous Close | 3.000 |
| Day's Range | 3.350 - 3.350 |
| 52-Week Range | 2.990 - 4.229 |
| Beta | 0.52 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About SHJBF
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company’s product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneous injection which is in phase III clinical trial for the treatment of t... [Read more]
Financial Performance
In 2025, SHJBF's revenue was 2.50 billion, an increase of 28.23% compared to the previous year's 1.95 billion. Losses were -875.17 million, -31.68% less than in 2024.
Financial numbers in CNY Financial StatementsNews
Shanghai Junshi Biosciences Earnings release: Q3 2026
Shanghai Junshi Biosciences released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Shanghai Junshi Biosciences Slides: Q3 2026
Shanghai Junshi Biosciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Junshi's Toripalimab Subcutaneous Injection Application Accepted In China For Bladder Cancer
(RTTNews) - Junshi Biosciences (1877.HK) announced that China's National Medical Products Administration (NMPA) has accepted a supplemental new drug application for its subcutaneous formulation of tor...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
SHANGHAI, China, Oct. 28, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Toripalimab SQ (code: JS001sc) in combination with disitamab vedotin for the treatment of HER2-expressing UC has recently been accepted by the China NMPA.
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma
SHANGHAI, China, Oct. 23, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated ...
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma
SHANGHAI, China, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated...
Shanghai Junshi Biosciences Earnings release: H1 2026
Shanghai Junshi Biosciences released its H1 2026 earnings on August 25, 2026, summarizing the period's financial results.
Shanghai Junshi Biosciences Slides: H1 2026
Shanghai Junshi Biosciences has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 25, 2026.
Shanghai Junshi Biosciences Quarterly report: H1 2026
Shanghai Junshi Biosciences has published its H1 2026 quarterly earnings report on August 25, 2026.
Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC
The supplemental application for Toripalimab plus chemotherapy as perioperative treatment for resectable stage Ⅱ-Ⅲ NSCLC has been accepted by the NMPA.
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
SHANGHAI, May 26, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the di...
Shanghai Junshi Biosciences Earnings release: Q1 2026
Shanghai Junshi Biosciences released its Q1 2026 earnings on April 26, 2026, summarizing the period's financial results.
Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026
Results from early clinical studies across Junshi Biosciences' innovative pipeline were presented at the 2026 AACR, featuring: JS212 (EGFR/HER3 ADC), the J
Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates
SHANGHAI, March 13, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to th...
Shanghai Junshi Biosciences Earnings release: H2 2025
Shanghai Junshi Biosciences released its H2 2025 earnings on March 12, 2026, summarizing the period's financial results.
Shanghai Junshi Biosciences Annual report: H2 2025
Shanghai Junshi Biosciences has published its H2 2025 annual report on March 12, 2026.
Shanghai Junshi Biosciences Slides: H2 2025
Shanghai Junshi Biosciences has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 12, 2026.
Shanghai Junshi announces NMPA acceptance of NDAs for toripalimab injection
Shanghai Junshi (SHJBF) Biosciences announced that the new drug applications for the company’s product, toripalimab injection, for 12 indications in the treatment of tumors has been accepted by the Na...
Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications
SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...
Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
SHANGHAI and HONG KONG, Feb. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discoveri...
Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)
SHANGHAI, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the d...
Shanghai Junshi announces results from JUPITER-02, JUPITER-06 at ESMO
Shanghai Junshi (SHJBF) Biosciences announced new and promising long-term survival results from JUPITER-02 and JUPITER-06 at the European Society for Medical Oncology, ESMO, ASIA Congress 2025. JUPITE...
Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis
SHANGHAI, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the d...
Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the d...